FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …
AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.
Related Stories
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 2 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 3 months
FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 3 months
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 months
FDA rejects Corcept’s cortisol modulator triggering setback / 6 months
FDA approves Rucaparib for advanced prostate cancer / 6 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Infectious Disease, Autism, Research Funding and look for the RSS link.
StackHealth Time Machine